ACRV

Acrivon Therapeutics (ACRV)

About Acrivon Therapeutics (ACRV)

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.

Details

Daily high
$2.44
Daily low
$2.31
Price at open
$2.43
52 Week High
$8.00
52 Week Low
$1.05
Market cap
74.8M
Dividend yield
0.00%
Volume
339,048
Avg. volume
581,693
P/E ratio
-1.11

Acrivon Therapeutics News

Details

Daily high
$2.44
Daily low
$2.31
Price at open
$2.43
52 Week High
$8.00
52 Week Low
$1.05
Market cap
74.8M
Dividend yield
0.00%
Volume
339,048
Avg. volume
581,693
P/E ratio
-1.11